ABC - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the AmerisourceBergen Fiscal 2021 First Quarter Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Bennett Murphy, Senior Vice President, Investor Relations. ahead. go Please

Bennett Murphy

President, morning, for Good XXXX you for Senior all Quarter Thank conference and call us Vice Murphy, Bennett this I Fiscal Relations. to joining Results. you. am thank Investor discuss First AmerisourceBergen's

also are President release measures. Joining Jim on CEO; measures Reconciliations available CFO. today's of Cleary, Collis, be and will GAAP and and call, President these and we at me provided Vice discussing website Steve press investors.amerisourcebergen.com. today On are are in Chairman, today's Executive non-GAAP our to financial

We accompany have our presentation also posted a today's investor slide to on press release website.

conference taxes. on forward-looking statements an this operating not about expectations basis, we non-GAAP EPS, financial but including, and During will adjusted limited call, income our and make to, business income

current are are on and change. and statements subject uncertainty based management's expectations to Forward-looking

any and AmerisourceBergen discussion release press most our to a key For no without company. call of the assumes we permission obligation statements, recent refer you of including expressed today's assumptions, update the cannot be SEC forward-looking our XX-K. and rebroadcast filings, this and risks to

opportunity get ask participants possible You per an will I question over within Steve. in hour. call one to by us you limit to ask many have questions your to remarks after participant for With that, order management. to will as We to today's that the as turn the

Steve Collis

resilience, teams chain. throughout create morning driven versus to the of capabilities our and everyone our and the has XX% by executed upon on XX% good and revenues solutions representing value Bennett, to XXXX prior delivered commercial our increasing with for fiscal $XX.X our start Thank quarter year. the leveraged exceptional Building a fiscal differentiated first of you, strong supply EPS call. year-over-year AmerisourceBergen growth billion year We the had our quarter. results, business to adjusted

critical our support and medical all facilitate patient think, act of associates to Our to plan access to focus-driven to and partners our culture empower treatments. continues decisively to

In Alliance strategic we as announced Boots expand and its we distribution January, addition results, acquire and agreement. in into majority to business entered of to Walgreens extend healthcare existing our a with the these transaction large

we innovative sought new ability our are expertise building patient to World agreements value provide for access geographies. and the partners, on differentiated enhancing ongoing complexities deliver on and in to providing support As our customers example, capabilities our global in to these to focus part deliver next means Courier manufacturing evolution services AmerisourceBergen’s manufacture solutions AmerisourceBergen’s proposition. our innovative and further helping of distribution said, have patient partners a its solutions value-added after with for a services highly key navigate access platform for support is partners scale. on of

us against the air logistics additional traffic in enabled worldwide track an backdrop During record leader have international support Courier’s of customers and specialty operational local changing a our pandemic, as World proven to restrictions, limited challenges.

of the and public partnering capabilities help Innomar for FedEx an hospital more are In with increasingly vital Thanks be important to support vaccine. trials services the distributor role able antibody have and been as private COVID-XX. Similarly, as our at to primary we distribution for COVID-XX. was playing are deep ways these to access of suite our clinical facilitate demand uniquely business both In is understandably public recover its solution and to the treatments receiving We to outpatients to both them the continue patient from our more complexity distributor support help partners treatments is preserve U.S., we be be robust proud COVID expertise, which and able them honored AmerisourceBergen part Canada, therapies, antiviral for and patient we the to continue health. to and and a at our and of global to industry our time services these to when peak. positioned are safety to

packaging at requirements facilities in innovative by scale and support team and storage Innomar as delivering the to important Our culture this collaborative safety, is safely AmerisourceBergen’s them specified as securely in the vaccines manufacturer. the temperature enabled and of our Canada across storing expertise solutions well and its work.

the as to both treatments. another is years in investment important the market is our or for important differentiated to distribution safety to COVID-related partners. portfolio focus capability foundational our all safety role distribution an of commercial growth solutions ability us part U.S. value safety deliver months, and We and is sourcing important and to teams our of several AmerisourceBergen continue play an providing spent the on and a enhancing system have it continue And in our those We on the our businesses. focus continues continued to building on an capabilities customers ability building healthcare important of leadership AmerisourceBergen’s clear to and and of is our distribution. last benefit pharmaceutical partners be for the differentiator important across analytics and more in our in our over leverage in strong data our expertise on even strengths as to driver proposition There customers.

have and appreciate collaboration. has strategic Over providers to relationships made long-term manufacturers it authority that AmerisourceBergen embrace the and with years,

enhanced areas efficiency with enterprises already opportunities serve we better commercial the from logistics, and to in in of month, us strategic distribution. Teams our growth by enabling and for companies associates will new the have U.S. to last transportation our extended of Walgreens our efficiency expanded customers. have expanding and opportunities This our agreed agreements. growth each identified both announced partnership partnership incremental create to allow and strengthen extending and we our As

initiatives for realize their all value Pharmacy business their as Elevate rise to to and of the Neighbor to and critical pharmacies have continue y X,XXX independent Provider incremental to communities whom derived Network Good care and independent from These we group As for adaptability value enabled ability our than One we increased more them entrepreneurs consistently pandemic. our AmerisourceBergen’s including this created challenges our partnership, these members. capabilities customers create have of differentiated the customers. for provide will customer is new pharmacy enhance

are the associates continued to enhancing empower that accessible have our the are tools the deliver them in by evolution to keep These environment. and segment, From and abilities leadership the the them and virtual products. customers on broader is healthcare services the to We long-term been We forward innovation customers’ phase innovative market business where clients pet they quality and swiftly pet relationships, step years. to client specialty in our a we eligible AmerisourceBergen’s have working and Health and succeed customers innovative as and XX/X of the network qualified manufacturer including over to communication with to ability focus of solutions strong to to the and global our next healthy. States. help Animal delivered their care provide patients to care our MWI inoculation needed network with United innovative this in business significant in of ability our to look strength services our In has support recently proud able partners efforts bolstering strength, their medications offer communities their connect administrator leadership and current a pharmacy to the to home support our services solutions. customer moved vaccination we to enter solutions took MWI delivery include ensuring distribution here traditional support

private and further AmerisourceBergen of leadership adding the pharmaceutical markets With scale innovation a be Walgreens of meet able strengthening expertise chain other our is services, breadth of new value we key global depth, majority Alliance platform Healthcare agreement to of added distribution of awareness combined as strategic is well. business and positions supply As its Alliance acquisition, footprint we our reach local global this Alliance both public and manufacture expanded expand broad our global positioned partner Through with entered into pandemic of capabilities partner’s month, value-added to increasingly better lead better AmerisourceBergen choice. Boots and we support and strong last a announced and acquire will services. The into a this healthcare pharmaceutical business. and a to our would locking and as which through nature to the capable

importance responsible investing accelerating remain enterprise a global our true stewardship. corporate continue our expands, initiatives talented and the in protect vigilant the supporting being associates. workforce footprint so further We protocols the AmerisourceBergen and policy the we work our culture, Driven our regions affect to suitable well-being waves does compensating our our including efforts of inclusion, and is associates. our understands As by and and in of we maintaining recent and frontline are value to and appreciates invest, peaks COVID all the our purpose, roles. work of prevailing and the associates and for protection enhanced safety safety still are importance doing remains unwavering. as the a Remote appropriately various diversity

based are associates. to our Great the We Work the our company. We certified empower we higher employees of our Underscoring for peers, efforts as situation associates indicators doing consistently world, prioritize all among score of significantly continue was AmerisourceBergen sure, and are of the and saw survey reported our I and the scores was support revealed job The experience around you the high safety their our will watching are positive health typical to am responsibilities. world. the associates and Company, leaders survey with U.S. as in Place following and all closely recently that to overall around

the recognizes having and sex veterans company. and us year identity and on well. accelerating non-discrimination corporate we with inclusion Additionally, Rights diverse our and a and of equality index culture recognized a Human as as corporate Equality gender support focus to AmerisourceBergen that personal To strategy diversity benefits, perfect place for equitable equitable with of this LGBTQ importance inclusive the our fourth an and and to is orientation, inclusive are equitable for due Campaign culture race, regardless work on row, the responsibility. disabilities end, score an even social to awarding of more policies, the in AmerisourceBergen become from or the people has best business gender,

diversity past we Council D&I D&I increased AmerisourceBergen and for the fair formed transparent environments. led conducted assessment, to a our and part of and workforce, a Over diversity initiate a inclusion, to have by support is the a CEO pledge commitment support ensure strives work senior global organizational D&I months, are executive engaged workplace. C-suite associate inclusive fields to a inclusive that more signed more a comprehensive and which a measured strategy and

proven diverse so in can we Our of become tools equitable value that culture these initiatives in area this programs is we the leader right will a have business and short-term, longer ensure and enhancer the a in inclusive and term. place the in

that is enterprise thrived to embodies and visually as by also associates one embodied culture, inspiring, Our new is last unveiled of success markets. progressive fueled the is confident our unity an design in our go innovation purpose-driven we spirit advancing new our by when we week. dedication displaying our while brand that with of a passion which brand, and a energizing, The

continue full potential. to committed As them inspires helps remain we differentiated business culture forward, and a and to advancing associates, unites move their them that develop our our we achieve

is I to direct of In this want associates strategic engaged, a culture time remains closing, strength business talents dedicated having and Our our a our advancing take a focus passionate result key associates. and to on thank and priority.

to to accelerate innovative have help to solutions across continued execute our our business partners. We

upon our empowered build purpose As across strengths AmerisourceBergen and to our we drive evolve, continues by will to enterprise. growth are the we

globally courage by, in and who being proud complexities and to further healthier access By and relationships, futures, – responsibility AmerisourceBergen innovation focus both many customer of with continued we execution and portfolio market create to upstream our face the enhance I inspired enable and facilitating of and our to continue specialty confident support and purpose-driven, and will well-positioned create on rise while strengthen supporting capabilities to customers, our supporting outcomes innovation. pharmaceutical downstream long-term teams We sustainable is solutions that effectiveness. positive be our challenges partners to growth.

more financials. a turn Jim? Now, over of to call for I review in-depth our Jim the

Jim Cleary

December will adjusted our on results Steve, quarter. My morning, Thanks, stated. otherwise remarks financial rates and and comparisons year today unless made Growth are focus prior against good everyone. non-GAAP the

a our results, detailed refer of to discussion release. earnings please GAAP For our

fiscal strong growth our year As clearly to XXXX a had with Steve businesses. our mentioned, we across start

to ensure continue teams businesses. worked entered November, AmerisourceBergen’s the momentum strong portfolio the As I clearly as Guided XXXX our stakeholders in for and creation our tenure all to experience. company teams support in and accelerated pharmaceutical we partners, differentiators unwavering back access the that focused of that to down on my by our associate ultimately of with key being AmerisourceBergen’s provide upstream a my AmerisourceBergen, entire share diligently with in well-being. and and solutions pride said patient efforts execution to both vital medications. can our value Throughout across purpose, health by fiscal helping a innovation purpose, driven quarter executed facilitate I our and for part to of our patient key in platform our strengthen is

success our protect, talent. and power continues our in to associates AmerisourceBergen and Our support invest

Turning now quarter areas this first provide in will to discuss commentary I main our results. morning. key

exceptional increase and the guidance. primarily will income I First, revision our businesses. Beginning of XX%, with with quarter will operating fiscal our our we upward our quarter review to to second, results segment cover I diluted adjusted $X.XX, across performance; due quarterly an XXXX adjusted consolidated results, EPS of finished growth first our the

revenue support is prior the due increase is of the XX Pharmaceutical of Health a segments. taken Commercialization in Services profit specialty of contributed basis XXXX, each profit improvement. The driven Services income associated the or write-down increase in a year margin and The basis to margin inventory write-downs million the prior segment and gross the Distribution forecasted businesses. due XX businesses margin the point XX%, could million, gross to Services year In group gross $XX.X in detail our compared driven profit and supporting the additionally expenses of which by the growth the was business profit of one-third PharMEDium not $X.X Consolidated point This margins operating by which million. our quarter. comparison significant reversal tailwind from year as the Global performance. XX%, profit protecting, quarter. reversal in billion, Group, revenue both segment Animal XX% quarter. was of increases with grew value will and reserves includes consolidated Health points a $XXX , gross improvement Our also both in frontline in increased growth products. of discuss our our improvement To our is margin exiting to a I quarter segment appropriately back portion This level higher and decline associates, I billion, was in and materialize. $XXX the up when sales a review in PharMEDium Commercialization profit and half fiscal driven and gross Pharmaceutical from Gross percent prior Distribution in the X.XX%, number revenue Other, particular Operating revenue inventory X% the operating more related growth to up expenses basis by operating was Global concentrating $XXX increased Animal of gross while to which increased to that X

from interest a rates. which expense, resulting income decrease to a interest increased due in net $X decline interest $XX now to to Moving million in primarily million investment

first rate of tax XX% XXXX. up from the fiscal effective was in quarter XX%, Our

million count XXX.X share modestly diluted declined shares. Our to

offshore. are This Regarding the cash of for of the start balance, in adjusted cash held our flow which with was and the on the quarter well review year flow ended our positions us we billion completes was track cash This quarter $X.X the million flow free guidance $X.X consolidated adjusted first $XXX cash billion with flow year. free after strong on our of the quarter. results. first cash, to cash and We free

our customers increased $XXX segment income billion, Segment increased businesses. at will therapies, by up points. including basis Pharmaceutical product I largest turn XX% margin across some broadly Beginning up of to revenue COVID-XX well Distribution to with XX% $XX.X sales, and our and as specialty operating results. about was growth operating as income our Services, Now million segment driven XX with

and in in a expense. the the of gross represented tailwind reminder, exit for is segment’s of operating profits roughly PharMEDium $XX half the income, which As half million operating other the a business

group and growth sales platform supporting the our group us operationally segment scale, of are This in COVID broadly of patients particular, Physician health portfolio strong as robust up prepared provide income throughout led distribution our to specialty reach challenges. Physician to would trends Excluding AmerisourceBergen’s continues and by specialty income differentiated treat practitioners quarter, and in continued leadership strong their products. tailwind, and positive performance a into customers capabilities Specialty and the values In operating Specialty a continued have growth by for our been increase businesses through significant to was expertise. our systems across Services the continue to Services XX%. deliver our in the its across sales PharMEDium driven partners operating specialty

growth business Additionally, are fundamentals to had we vital in we now health strong, seeing our of antiviral overall significant biosimilar customer segment. Health for also antibody the The access to facilitate as continues Systems therapies particularly utilization patients. to COVID-XX business are this and increased helping systems be as

adapting $XX was AmerisourceBergen Animal Division income strongest Health growing on While to which Other Courier customers and and encouraged I and its interactions. for adoption XX% strength physical to of three at are biosimilar across cell capabilities. turn segment, ongoing relationships, increased Commercialization million Operating for need Systems. MWI specialty provider now Courier. side, total we in to focus differentiate direct-to-patient the gain increased standards Global be veterinarians will continued complexity, companion the see well Group global engagement to from an pet the as and the Services the up In particularly the including MWI quarter, Health to driven their ownership, and World operating as the is most and of from business World $X.X impactful primarily process limited the on choice in is segments. due continues in benefiting the businesses revenue where logistics growth are has includes solutions of by benefiting and billion, MWI. Specialty increasing care to customer commercial utilization that Courier virtual there increased initiatives trends gene growth and or now World and growth utilization was of Consulting XX%, up itself

in Courier’s exchange was our foreign note completes augmented This will the of review rates. World the segment results. rate I growth currency by that Additionally, quarter

the XXXX. include will I fiscal This updated So announced does turn in not guidance of acquisition from now January our guidance. to Alliance XXXX contribution Healthcare any financial foreclosed

growth the a positive quarter our to first outlined, across continues I Therefore, AmerisourceBergen $X.XX, press exceptional we from said delivered $X.XX as raising new to in reflecting As XXXX guidance to our fiscal fiscal further we are release, to $X.XX of EPS and to guidance business X% of XXXX. morning’s range f we just as X%. in this expect adjusted trends $X.XX of growth into move our range

fiscal for growth We updating Revenue growth than percent financial metrics Other. are Services Distribution have to now other as range, Pharmaceutical is be also and XXXX. in both expected guidance we high-single-digit the better expected in seen

Next, committed percent the especially remain high-single-digit we operating grow investing to associates range. safety mid the and those We expenses the and on expect to frontlines. well-being to operating of expenses, our now in in, ensuring protecting

for income Commercialization positive which our This now the first Health Other, of operating operating business. to expect of income our the significant the quarter a and believe reflects Global trends percent in grow guidance operating improved high-single-digit operating operating positive Turning our businesses. range, given and in we raising the grow result in income, growth now as in result It income continued we Animal will range. to to across income overall expectation in Distribution to now Pharmaceutical mid trends the is high-single-digit the a range high-single-digit also

fiscal narrowing shares expect a associated the shares All finish outstanding, million needs other to cash Lastly, and from unchanged. the are we to XXX given with now Alliance of regarding XXXX year range remain our acquisition, guidance million financial XXX million XXX guidance metrics the we for around outstanding.

further to will EPS associated significant March onsets the the customer guidance, by fiscal to tough strong quarter value-added and I serve our for innovation commitment with XXXX our while which we positioned our key be will are the global while the enhancing pharmaceutical-centric quarter strengthening their purchases full on and comparison the provide to forward, and on that our platform for focus Alliance execution differentiators increased AmerisourceBergen second at business note not In quarter to will COVID-XX. a will relationships, Healthcare excellence, partners build strategy, expectations, XXXX solutions. sales patients. we services a expanding our quarter, excited is Regarding continue of had capabilities drive do March closing, quarterly how our customer and impacted and acquisition well our by our reach

the to importance on quarters spoken team. show innovation and and AmerisourceBergen’s track the business. proven expectations to outcomes of important work that capabilities resilience are have detail the value-added contribute word forward resilience to globally. great Alliance understates Clearly, the teams pharmaceutical welcoming our business we as and leveraging help results remains several our These in and Our our of of patient look I purpose-driven around expertise acquisition our to the Healthcare about and strength the access positive past solutions have provide

upcoming Responsibility drive futures. to be communities global report, in being while for providing work business growth, an with frameworks. are how in people, you our contributions to Corporate and to can that of sustainable your in Thank by for united perspective, value and know thoughtfully, purpose the show long-term We with we create AmerisourceBergen. all our healthier align sustainability positive our and areas interest our and our in AmerisourceBergen fulfilling and of We our leading creating commitment stakeholders responsibility and business doing where many responsible will Sustainability these update by doing we Global practices live planet making business on the

turn start I to Operator? over to call the the Now operator Q&A. will our

Operator

from Santangelo Please comes ahead. first Securities. The of question Instructions] Guggenheim go Glen [Operator today

Glen Santangelo

the all Jim, guidance. hard Good I the morning Yes. fiscal XXXX in thanks want It’s for on my the pieces kind Thanks. question. with to taking reconcile you to guidance. and moving just of follow-up

again Alliance with company month raising guidance Healthcare the are the today than expected raised XQ You’ve when now and the better acquisition it results. these announced you last

about maybe changed has prepared your the So, fiscal Thanks. taking help in remarks? benefits the think consideration the of called maybe year beginning and some into could you what of incremental out you COVID-related release us from the

Jim Cleary

and were lot the and of in end trends Commercialization Glen, this and completion for November and guidance. found be pieces in guidance to and in and that and our all, the guidance thanks Animal the the to it’s question. some We guidance of I’ll first happy seeing across about this lower moving increase year I’d a our in that our a businesses of higher that talk stage Health. positive original up up healthy first of of at at Distribution our are $X.XX $X.XX both quarter. fiscal is course end business say execution the we early the the after Pharmaceutical And due across really of at strong in guidance really fact versus

include, including very we based And of continue very treatments. that positive performance performance on Physician in strong in continued Pharmaceutical trends Systems services, Distribution COVID Health some to the are distribution good are in see also Specialty

Health, growth We Systems Commercialization and Physician MWI and customers World we Animal and largest positive and at across are very then seeing are our in in good our strong And of growth businesses. in growth both some seeing biosimilar trends. Services and broadly QX Health services with Specialty continued Courier strong in

million future QX, these to final We to first our also course pieces of repeat remarks, tailwind my beyond exit moving are that exit now guidance I’ve mentioned a $XX positive of about doesn’t noteworthy some QX, in trends which all of the there think prepared to we as related call had quarters. overall just PharMEDium tailwind the in so, PharMEDium. out in in of related, And

related We in my which in That then And begin also also in mentioned rates remarks, $XX utilization. million course prepared to doesn’t a I write-down recovery biosimilar of repeat growth GP QX benefit had, future quarters. in QX, to which year-over-year the we was lapse significant the to in QX. inventory

with three year. contribution assumptions, key this of to by And first will regard the the the the therapies operating of fiscal point biosimilars our guidance the in will lower fiscal fiscal the to continue second XXXX. quarter, so but particularly to the or than significantly balance in from we a assumes of quarters our And first not half be that income our also, COVID of quarter XXXX same grow during last year of they saw rates then is were sales the guidance at

Regarding are as the we called XXXX, Alliance part the in few has in to that that recall, the acquisition of no repurchases that acquisition. And then per we our acquisition back the below is just associated we costs healthcare And then, lower finally, last We year assume OpEx, issued a low closing there and fiscal have associated also growth acquisition Glen, you’ll with carrying there as the we share is in the a couple as the importantly, starting notably months And lower to for things the year in the had in compare and the operating prepare of particularly guidance before benefited year, travel. line. income costs. guidance fiscal our half expenses, second year. of fiscal particularly out the OpEx from half

good say this, the very guidance. the I’d particularly by overall, we in increase a So, about in strong increase are we’ve done it’s results evidenced feel good guidance, year. excellent as fiscal early QX that The the in fact the and our fundamentals in business given

Operator

go comes Coldwell Please question of ahead. Baird. from next Eric The

Eric Coldwell

you headwinds. to I raised that here my then the for before second say, things guidance a seven month first, just Jim, have Thanks. time you and in question, are tell saw you

of headwinds and you’ve manufacturer underlying services cold to thought think we or $X at I was case the least has lot with performance season. am sure, flu is. seeing it pretty am and billion call be fantastic in that’s I than wouldn’t quarter be the that a are cough low talked revenue street it. access past guess, the scrips these year interested, in maybe lived with patient So the more the perhaps service and a really a I it about I if really bit for we the low mean, it rest I

COVID You’ve had am willing could quantify distribution with far to talked impact lot today? you to the Health that even margin on about you’ve if manufacturers. highlighted exclusive you’ve I a you if a curious times therapies I possibly Systems the few several know and deals and are go impact antibody revenue antiviral that and maybe the

Jim Cleary

Sure. Absolutely. Yes.

in $X.XX EPS. second significantly sales be will some thank during been and Yes, the guidance comments temporary net quarter thing business will impact expenses lower the impact with just assume and mentioned. this bonuses first regard effect balance also quarter of ramp quarter pennies the is on the your net in represents strong. COVID the for execution I things And our included net out was is COVID a due you With payroll associates, of quarter to COVID of I that quarter. during year, COVID and the very the benefit overtime the pay of and all, therapies. our call $X.XX fundamentals that $X.XX important couple in EPS the work of think But of the quarantine to the described First approximately that of one of associated it cost are for therapies, frontline particularly are the elevated the health the our the that performance of cleaning for businesses includes and we were and EPS of just be have our positive the the that during doing like, important to does associate of I distributing things expenses And therapies reflects which half to like year. of

Operator

of JPMorgan. Please Lisa from go comes ahead. question next Gill The

Lisa Gill

Hi. as Jim parts, think moving relationship with morning. as quarter, Thanks just understand we just about much. And to couple Great a well very good and the I want Walgreens. renewed

generally, of to is about understand what question. forward, margin then will that extended overall relationship this with So, structure a to Walgreens as up utilization underlying else something anything secondly, we business of, renews like some end look the have the when you going you and about at the I just you think pricing there do my of is And trends. wanted new length or attached contract extend amount

were cold do we into have some seen You business? about in on quarter forward how the March months your talked And impact going cough and ago. the utilization? year first of were flu pulled March here quarter what the around But that a think general things there that about you

Steve Collis

Lisa. take for question your [Indiscernible] this. Hi don’t I I’ll comments. question. answer Thanks the first if

guidance. benefit I taking key thanks a get been the much more terrific brought a we has our also the of pricing There more that our competitive Walgreens, And stuff our But generic and the competitive think of customers. way deals But, got remarkable we really just also think in I industry with leverage. was for was to again pricing agreement on our to ourselves should a only – ways, a which the distribution not back to scale structured generics. Walgreens and deal in I and to to feature. were think XXXX can you course big and was the it many to hold change industry. we able but

So, took and the next mechanisms has contract areas I and – into that this was agreement which mix, go working account many changes We really seek it’s the through. so and like way brand self-regulating think that. will very [Indiscernible] is of in through brilliant up phase we XXXX

really to of part didn’t I’ll the adjustments So, mechanisms because then make market answer. second we comprised. were any your to Jim And really leave question, have the

Jim Cleary

Yes.

regard relationship, that also of the part we Walgreens and are really with potential I that targeted your about was agreements will we then, working Distribution we to on on things the like really second at the there. regard And have and be sourcing the going on with expanding and say, utilization, to we on like this synergies around The excited – just initiatives are Walgreens the all question aren’t point. utilization calling with on them to and efficiency anything growth with out January

strong we in of across in just first and businesses. And the also and I we We in Animal really sales company in we Systems. is, and probably specialty services and in our really data, say good we’ve really and our first which given our in quarter focused and trends businesses on businesses, specialty, our saw volume and But just talked trends clearly our in broadly businesses strength seen a few I’d of throughout across Health we of year, trends the remarks. the sales physician focused our many trends Distribution trends profitability the But prepared Pharmaceutical February. saw Commercialization on are strong both very and fundamental Services Health first Global I’ll was quarter still then on the strong days as the businesses that’s about comment what

Steve Collis

Thanks.

Operator

Robert question Sachs. comes Jones ahead. from Goldman next Please of go The

Unidentified Analyst

as for this year-over-year. Hey. calling XX%, fiscal easy coming are we somewhere – morning. I the impact. know guys south like cadence COVID Other have the the to of just and know around would deceleration growth for the could is you segment. of the out be sequential And that for questions. drive then, I the year the to somewhat Is about Other growth in the Bob balance know comp the attributed was what on is I over Thanks wanted of obviously and think to XQ. over looking I be year, overall you pretty I This that. talked are just that strong in course there segment, just might wanted on guidance Kevin taking anything any helpful. of

Jim Cleary

Sure.

its to probably asked direct-to-patient we So, just navigate has of partners the you had up I’ll Courier up to value for it’s complex with being able on one did in income global become Other things out for and with and opportunity strong to manufacturers thing, that environment. really environment segment calls XX%, manufacturer the capabilities solutions quarter complex COVID regard with the that, like it the about XX% a help segment, is very World with prove revenues impact an start more things logistics Other and to have operating like call been best-in-class COVID really the

XXXX COVID forward so is in your the pull second of question, COVID. the as at then, we’ve part really we a And I year, that of had show think cadence the so, really for guidance And thing talked remarks. that you And in Courier the fiscal and about through with guidance. with gone March of first look reemphasize kind particularly its strong the March I’d the prepared during the of the has guess, I of sales And month cadence value. there a one was World the quarter to quarter enabled question has we the do of onset the to

comp. quarter the bit March little makes a XXXX that so, tougher And

Operator

Goldwasser question of ahead. from Ricky go next Stanley. The Morgan Please comes

Ricky Goldwasser

Good Hi. quarter. Yes. morning. on And the congrats

you for JNJ But, So, And are that outside we vaccine, kind thinking points about the I not are the evolve? to yet do doing into think I kind marketplace. of be U.S. the of of specialties opportunities is assume approval you what understand the waiting market access could vaccine how going the that change the U.S. some in could for U.S., the

you So, how there? think about potential role do your

Steve Collis

for Hi, Ricky. Thanks the question.

highly be I the do is to fixated the believe and we months. Summit. pharmaceutical on vaccination couple a not tremendous on amounts next when on of course, chain as So, distribution get couple and And Dr. as I will had of patients this. point that the and I kind getting of will in the to September we at Dr. problem. all sophisticated. actually believe efficient guest impediment people And Commercialization was And are supply is a calls the Gottlieb [Indiscernible] people the we any U.S. it’s distribution just of ThinkLive supply – our will that of

and we got really whole and the that As companies ensure products also as and it really to COVID seen access been as chain and about has being the talk already visible to enhances the you has do talk appreciate true then and to the as this importance have will so U.S. organization that’s the a that I – to us disclosed efficient that getting appropriate market be of lot timely AmerisourceBergen U.S. has obviously accurate infrastructure delivery. about enough think is. we that without much know, I in supply distribution we’ll pandemic the like not

distribution Canada. the We are doing in

is Canada sourcing the course, product Europe. Of from

some Courier very that role of proud we also story remote doing logistics. get we’ll expire. our had before at again on Summit We that the business is are Norway to – ThinkLive World of some products actually complicate are We heard to where to and proud and that the

just vaccine we’ll talk let say has So, it and that everyone course I in terrific involved got challenges am to More that, about our company would them a and in distribution sure future tell. great also this stories large is of are, these role playing stories unique distribution. of logistics I

talk to about for is same well ABC distribution. positioned and Thanks. So, the in logistics be

Operator

ahead. of next go The question Research. comes Nephron Please Eric Percher from

Eric Percher

COVID. about Gilead demand you Has the channel, you. we additional Steve, for ask of publicly. insight track on track where can channel. distribution for Are and you but product exclusives to the the Thank Lilly maybe the products by in I it’s hospital growth seeing hard had you think hospitalizations some I’ll certainly number been And to hospital dominated talked the products?

just been hospitalized? number about it it has So, simply therapies more adopted or the has been

Steve Collis

a the reporting. have AmerisourceBergen has all are role or of and products unique playing we XX data them there XX that on been – almost It’s about prominent because of No. UA in capabilities

licensing. just the hospital about U.S. it – our to and demand registered in and call We in customer really disability a term with lot demand. the then, unprecedented a limited competitor a waves supply demand have and that as used non-linear every And of

in won’t it’s as first inputs aren’t just therapies time the demonstrate from we it’s and and So, that. you role opened be on would demand we will and that the patient course that and see quarter. of quarter-to-quarter But quite played extraordinary fluctuate the lot based much explaining so, hope in that still that as there a of

So, thanks.

Operator

Hill is question next Bank. go Please of The Deutsche George from ahead.

Unidentified Analyst

margin expand Thanks Can is conversion on in what have expansion Hi. of segment? the much larger Charlotte their taking This we profit And drug is brand more core in – question. you the expected for for my growth on the gross incentive. drove would George. given

just could color provide you there? if So, any

Jim Cleary

the some product as XX also kind me treatments. Yes. of Sure. COVID-XX Health Health performance a like Physician as XX% let Yes, that good go Specialty that, it’s points Systems Physician One we’ve we of were quarter. did specialty and margin through Specialty I Systems. Health things the included during as and Systems, up in biosimilars. well see in But drove or talked it about included very increased that. basis sales Really, was both lot and mean, Services Services margins

of the so, biosimilars. second that in course, kind of biosimilars year-over-year now. to And of see those drivers fiscal one comparison was on, significant of we utilization quarter our in – significant But we lapse we in start positive really commented as of difference trends And we continue began during the and gross to the the to margin quarter. that see increased XXXX

continue in getting things so, perhaps growth that biosimilars, lower Other we’ll to businesses. but are at to a back higher our rate. growth in seeing overall margin question, helped And your see our margin, we

in thing the So that Specialty half are I’ve OpEx. higher about profit. is, our And World and in other higher benefit businesses. talked those GP the – also the the Physician exiting About profit. helps Courier Growth business we called gross in MWI got and our of margin was margin Services, other into helped our then businesses gross PharMEDium out half

then, reversal of our the that our profit And also the inventory quarter. helped helped profit. reserve I mentioned, gross during gross write-down that that the So

the performance So, there and businesses of excellent quarter. margin particularly strong of during things, was the really of our a were number our but was performance different the higher businesses

Operator

Rhyee The ahead. go of is next question Cowen. from Please Charles

James Auh

is on for Charles. James This Hi.

drove in that maybe business in business? more dynamics of other can performance and services are that quarter? MWI the strong about, And World noted which in the you performing talk operating But Courier, how You’ve profit growth. the consultant is seeing you some just

Steve Collis

Yes.

and our kind to a to out business business really business business. perform labs we be are our that At out important the view nice continues an rolling advantage going Our part rolling labs Fusion – our of we business, competitive of well Fusion for fully us. and It’s Consulting into instance, for well. is and

manufactured And some important of good services, synergies us, they’ll manufacturer with so, have services businesses are things business. very our that Alliance’s to businesses important consulting really provide

So we that to collaboration. forward look

said, and just various and were whole listening company trends are held issues, grow performance week. World expected Summit manufacturers’ took we and to And as businesses part quarter is and our so, I the the reimbursement continues businesses. and the there first this Courier the from ThinkLive to important stop ran really of cell quantity is the therapies, to virtual access accumulators, issues it be us able And focused It’s and we as just that – to on away overall, I co-pay the Commercialization gene myself one was MWI like minds. super And during I’ve had emerging that to provide. hallmark listening because – fast

commercialization – conference in product showed look I really the have the it forward that been this our innovation, lot side We seeing people rest understand the and up because that couldn’t of way proud to expertise. emerging on manufacturer such excellent people AmerisourceBergen’s I cycles, the and process, trends that this was really understand of have more

You do think this have well remarkably and commercialization the years as displayed complex our people area we outstanding so other World of for the Courier it’s we we leadership it work many many in such and and does, we businesses. collection, of so have that

the So, question. thanks for

Operator

Please go Barclays. of Valiquette ahead. Steven from is question next The

Steven Valiquette

morning, Thanks. everyone. Good

has pricing brand expectations. light maybe just am check brand calendar I to the pricing just on the want price early So, XXXX. been I in your generic box guessing in and that taken of

overall attention actual price would activity line characterize a bump your priorities. of there also with going or generic some has the just because increase to bit pricing side, On little generic is is a up you called be that your in in

there be color will great. Just little Thanks. more

Jim Cleary

pricing in for the year. original trending the brand with Hope expectations line say could generic line our expectations, we with had in both Yes. for are and we

but still You in that We then saw of generics. about are deflation experienced the similar a range we in moderated deflation and expecting generic about in And fourth end we we XXXX levels saw fiscal at there of XXXX. the XXXX off leveling was generic that that the asked year. in quarter, general

in are both with So, our trending I said, expectations. line as

Operator

Singh question Please next Credit of ahead. Jailendra go is The Suisse. from

Jailendra Singh

the you the production drill trends down when more to expectations quarter, can get market, terms you XXXX want to of MWI levels what companion? of as your fiscal I and recently as Actually, the Help well are Maybe business. you into in companion parse market please. it more little in you. pre-COVID strength for some both color Thank expect comes a little the out saw and remainder your production us of back there in and a getting of degree bit to

Jim Cleary

Yes.

about Animal the that, the which by from excellent strength and market, revenues, companion of Health really future our business the strong and during that execution be strictly customer just animal by quarter whether really very COVID in the we both underlying now. just I’ll the been all, The growth focus feel OpEx, very but right team. it’d production execution the say service was of in GP, quarter customer First companion of more animal market market. has optimistic impacted came the animal is The and production strong animal environment, the

Operator

Please The ahead. Caliendo next question Kevin is from go UBS. of

Kevin Caliendo

Hi. ask when or to a for does how and your Thanks close now know bring here. the to and is you what like out done it sheet hate in What’s of timing but given lump also settlement over balance am how terms specific your XX just but up the one end settlement going your very expect of we to or if for should competitors you years? take flows? to I my you how not sums of look reserves, call. extended I taking play a seem expectation like cash that would would are we that, anything opioids, given like

Steve Collis

Yes.

an the fiscal year our end parties. our of end. see with accrual We continue discussion progress at September, the We to various in – did record year

the liability profitable. As believe - and

the couldn’t to it. AmerisourceBergen utilize I expertise can going With the quarter. more execution close really proud the be our unfortunately limited today’s to that deliver we that, capabilities call. solutions comments our proves continues out Thanks I to about and for Given of am in we It last for understanding. ongoing discussions are partners. in make scale, differentiated

to with to leadership our foundational strategic Our long manufacturers partnerships pharmaceuticals, on success. and in investment focus be specialty, and history and continues of customers strategic

with the inspired build ahead opportunity our be focus transaction, I also to with differentiated workplace. to continue the for our Alliance look on advancing culture excitement on by platform we talents, As and internal

today. by to associates attention you of and create our Thank guided are healthier for time We responsibility proud our and futures. your

Operator

for concluded. The attending Thank now presentation. conference is you today's

disconnect. now may You

Cencora (COR) 4 Feb 212021 Q1 Earnings call transcript